Bruker (BRKR) Receives a Hold from Citi

Citi analyst Patrick B Donnelly maintained a Hold rating on Bruker on January 2 and set a price target of $40.00. The company’s shares closed last Friday at $48.11.

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

B Donnelly covers the Healthcare sector, focusing on stocks such as Exact Sciences, Illumina, and QuidelOrtho. According to TipRanks, B Donnelly has an average return of 4.3% and a 49.68% success rate on recommended stocks.

Currently, the analyst consensus on Bruker is a Moderate Buy with an average price target of $51.00.

Based on Bruker’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $860.5 million and a GAAP net loss of $59.6 million. In comparison, last year the company earned a revenue of $864.4 million and had a net profit of $40.9 million

Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BRKR in relation to earlier this year. Last month, Richard Packer, a Director at BRKR sold 5,028.00 shares for a total of $243,204.36.